Molnupiravir, an oral antiviral treatment for COVID-19

W Fischer, JJ Eron Jr, W Holman, MS Cohen, L Fang… - MedRxiv, 2021 - medrxiv.org
… Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID…
efficacy of molnupiravir in the treatment of COVID-19 ( ClinicalTrials.gov NCT04405570 ). …

[HTML][HTML] Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients

A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
… trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days
after the … Participants in the trial were randomly assigned to receive 800 mg of molnupiravir or …

Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults

Y Caraco, GE Crofoot, PA Moncada… - NEJM …, 2022 - evidence.nejm.org
Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small-…

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

WA Fischer, JJ Eron Jr, W Holman, MS Cohen… - Science translational …, 2021 - science.org
… , molnupiravir treatment completely blocked transmission of virus to untreated animals,
suggesting that early treatment … This study was initiated as a single-center, single-dose study, …

Molnupiravir: A new candidate for COVID‐19 treatment

F Pourkarim, S Pourtaghi‐Anvarian… - Pharmacology …, 2022 - Wiley Online Library
… of the molnupiravir administration in the treatment of patients … of molnupiravir on the
appearance of drug resistance-related mutations. Therefore, molnupiravir can be effective in treating

Why molnupiravir fails in hospitalized patients

AN Brown, Y Lang, J Zhou, EJ Franco, KC Hanrahan… - Mbio, 2022 - Am Soc Microbiol
… that early intervention with molnupiravir resulted in a greater … explained the failure of
molnupiravir in hospitalized patients … regimens for the treatment of viral diseases. This contrasts …

Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs

LD Saravolatz, S Depcinski… - … Infectious Diseases, 2023 - academic.oup.com
… -19 were randomized and treated with molnupiravir (n = 710) … reactions in the molnupiravir
treatment group were diarrhea (2… authorization for molnupiravir 200 mg capsules, Center for …

Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial

MG Johnson, A Puenpatom, PA Moncada… - Annals of internal …, 2022 - acpjournals.org
… We conducted additional analyses to evaluate additional potential benefits of molnupiravir
for the treatment of mild to moderate COVID-19 based on clinical markers and the need for …

Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19

JR Arribas, S Bhagani, SM Lobo, I Khaertynova… - NEJM …, 2022 - evidence.nejm.org
molnupiravir in patients hospitalized with Covid-19. … received at least one dose of molnupiravir
and 75 of placebo. At … (55.5%) molnupiravir-treated and 46 of 75 (61.3%) placebo-treated

[HTML][HTML] Hospitalization among patients treated with molnupiravir: A retrospective study of administrative data

G Prajapati, A Das, Y Sun, E Fonseca - Clinical Therapeutics, 2023 - Elsevier
Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to moderate
cases of coronavirus disease … of adult patients treated with molnupiravir in an outpatient …